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Background: Different studies have investigated the effects that changes in drug appearance have on the control
of chronic diseases and drug safety. The main objective of the proposed study is to evaluate if changes in the
appearance of the packaging and presentation of drugs having the same active ingredient are related to a
decrease in adherence and an increase in usage errors for chronic treatment using antihypertensive (enalapril and
amlodipine) and hypolipidemic agents (simvastatin) in patients ≥65 years old, over a one-year follow-up period.
Methods/Design: We propose a multicentric observational longitudinal cohort study with a one-year follow-up
period in 8 primary health care centers (PHCC) in the Community of Madrid. 259 patients who are ≥65 years old,
hypertensive and/or dyslipidemic, undergoing treatment with enalapril and/or amlodipine and/or simvastatin, and
under formal follow-up of chronic patients in primary health care will be selected by simple random sampling. The
main outcome variable will be a final combined variable (adherence and medication usage errors). Other included
variables will be: sociodemographic and clinical variables of the patient, degree of disease control, drug taken,
number of changes in the appearance of each drug by the pharmacy, and the type and frequency of both
avoidable and non-avoidable adverse effects during the follow-up period. A descriptive and a multivariate analysis
of the variables will be carried out by means of a logistic regression model, using the final combined variable as
the dependent variable (error and/or inadequate usage of the drug), and variables shown to be related to it during
the bivariate analysis as the independent variables.
Discussion: For drugs of the same active ingredient, the effect that different package appearances and presentation
may have on the safety of patients undergoing chronic treatments is unknown under the new legislative framework.
There are various initiatives that promote the iso-appearance of drugs: “If they are the same, make them look the same”.
It is to be expected that older, multi-medicated patients with chronic pathologies will be the ones under a greater risk
of suffering from this problem.
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In 2010 the Spanish National Health System (NHS) paid
for 958 million prescriptions according to data from a
report by the Spanish Society of Public Health and
Health Administration. Due to this massive exposure of
the population to drugs, and to a non-negligible percent-
age of patients who suffer avoidable adverse effects, the
risks associated with drug usage acquire an enormous
relevance from the public health perspective [1].
In 2011–2012, legislative changes have been intro-
duced in order to lower the pharmaceutical expenses in
the NHS that affect drug prescription. The Spanish law
Real Decreto-ley 9/2011, from August 19 [2], requires
the medical prescription to be made according to active
ingredient, official Spanish denomination, or common
international denomination. This way, homogeneous
groupings are established for the same active ingredient
in order to facilitate the interchangeability of drugs.
Later, the Real Decreto-ley 16/2012, from April 20,
which addresses urgent measures to ensure the sustain-
ability of the NHS [3], requires dispensing the lowest
priced drug out of all the pharmaceutical bio-equivalent
presentations, among other measures.
Since the entry of these laws into effect, the doctor
writes the prescription according to the active ingredi-
ent, with some exceptions (therapeutic needs and lower
cost), and the final choice for the commercial brand is
determined by the pharmacy based on the lowest-cost
criteria. Therefore, the pharmacy can make the neces-
sary changes in order to adjust to the economic criteria.
In this new legal framework, the patient can receive
multiple presentations of the same drug when periodic-
ally renewing a chronic treatment using the same active
ingredient, with different shapes, colors, and sizes of
pills, excipients, and packages.
Without doubting the proven clinical efficacy of gen-
eric drugs or prescription by active ingredient, this situ-
ation generates worries in the medical field about the
fact that these different presentations of the same active
ingredient may increase the risk of drug usage errors in
chronic treatments, since multiple changes of commer-
cial brands can be made at the pharmacy [2], which may
increase the risk of drug usage errors by patients. Ac-
cording to data from the APEAS study [4], which
employed an observational design to study the safety of
patients in primary care during standard clinical practice,
examining over 96,000 consultations in the country during
2007, the prevalence of errors is estimated to be around
1.01%, with an emphasis on the fact that in 48.2% of the
cases the causes were related to medication.
Various authors and organizations have developed rec-
ommendations for alerting of this problem [5,6]. The US
Institute for Safe Medication Practices (ISMP) recom-
mends generic drugs keep the same appearance as theoriginal brand, or a standard universal labeling be used
for bio-equivalent medications. This Institute has a Na-
tional Program of Medication Errors Notification in
Spain (ISMP-España), where errors of mistaking differ-
ent drugs with similar packages have been recorded, as
happened with Renitec® 5 mg and 20 mg and Zocor®
10 mg and 20 mg because of having similar packaging.
In Spain, various scientific societies (Spanish Society of
Family and Community Medicine, Spanish Federation of
Community Nursery, and Spanish Society of Attending
Quality) have signed a manifesto under the motto “If
they are the same, make them look the same”, demand-
ing actions so that packages of drugs containing the
same active ingredient show a common appearance,
which has been denominated “iso-appearance” [7].
Different studies have investigated the effects that
changes in the appearance of drugs (package, shape, size,
color) have on the control of chronic diseases. Of par-
ticular relevance is a systematic review by De Craen et
al. [8], published in British Medical Journal, including 6
clinical trials that evaluated the effect of the color of
pharmaceutical drug presentations on various factors,
for example relating the drug color to a stimulating or
depressive effect on the nervous system, or to the loca-
tion of the effect. In addition to the placebo effect that
different drug colors produce, color changes can confuse
the patient, increasing the risk of errors. On the other
hand, the change that happens at the pharmacies when
dispensing medication with a different look may also
affect the clinical control of the disease. The effects of
drug appearance changes are centered on 2 mechanisms:
medication errors (mistaking drugs, duplicating doses)
and lack of adherence to treatment (either due to or in-
dependent of medication errors).
Undoubtedly, the most vulnerable population to these
possible mistakes is the older, multi-medicated popula-
tion. The changes in pharmaceutical presentations may
mean an extra difficulty since they often suffer from vis-
ual deficiencies, and even cognitive ones, which can in-
crease the risk of mistakes [9]. All this can generate
confusion, forgetfulness, or duplication of dosages,
which worsens adherence to the treatment, and there-
fore endangers their safety and even disease control [10].
The Spanish Ministry of Health, Social Services, and
Equality itself establishes the investigation of the safety
of medical treatments in the >65-year-old population as
a strategic research line [11].
Lack of adherence to treatment is a problem of great
relevance [12]. In the 2003 Geneva convention [13], the
World Health Organization (WHO) already warned that
only half of chronic treatments are followed correctly,
and that adherence to them is an important modifier of
the effectiveness of health systems. Among the causes
for the lack of success of chronic treatments, the WHO
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assisting the patient, the health system, the characteris-
tics of the disease, the treatment itself, and factors re-
lated to the patient. However, there are no studies that
have evaluated the effect that repeated presentation
changes may have on treatment adherence. Strategies
have been proposed to avoid changes in commercial
presentation, some of which imply manufacturing drugs
with specific shapes (for example, the famous blue dia-
mond of Viagra©), while others suggest directly advertis-
ing the specific look of the pill [14].
Hypertension (HTN) and dyslipidemia are two very
prevalent chronic pathologies in our environment. The
prevalence of HTN in Spain is estimated to be around
35%, and almost doubles in patients over 65 years old
(68%); as for hypercholesterolemia, it is around 50%
when considering levels of total high cholesterol (HDL >
200 mg/dL or people under pharmacological treatment),
or 44% if considering high levels of low density lipopro-
teins (LDL > 130 mg/dL or under pharmacological treat-
ment) [15]. The 3 most prescribed drugs for these
pathologies (enalapril, amlodipine, simvastatin) have
been selected for this study, which have a high impact
on the NHS due to the volume of prescriptions and the
high number of patients who chronically consume them,
according to data provided to the study auhors, by the
NHS. The possibility of repeated changes at pharmacies
for this group of drugs can be high; in the Spanish
pharmaceutical market, there are currently 45 different
presentations of enalapril 20 mg, 40 presentations of
amlodipine 10 mg, and 47 presentations of simvastatin
20 mg [16].
In primary health care, we find ourselves in a suitable
framework to be able to observe under conditions of
standard clinical practice the real effect of these legisla-
tive changes on patients with chronic diseases. The for-
mal follow-up of these patients in primary health care
will allow us to study the possible effects that appear-
ance changes may have on adherence, possible usage er-
rors, and clinical control of the disease.
Aim
The main aim of this study is to evaluate if changes of
drugs with different package and/or presentation appear-
ance for the same active ingredient are related to a de-
crease in adherence and an increase in usage errors, in
patients ≥65 years old, undergoing chronic treatment
with antihypertensives (enalapril and/or amlodipine) and
hypolipidemic agents (simvastatin), over a one-year
follow-up period.
The secondary objectives are: to describe the number
of drug changes made at pharmacies, estimate the fre-
quency of avoidable and non-avoidable adverse effects
during the follow-up period, describe the tolerance ofpatients to the dispensed drugs, and study if the number
of changes is related to a decrease in the degree of con-
trol of blood pressure (BP) and/or LDL cholesterol.
Methods/design
Design
Observational longitudinal cohort study with a one-year
follow-up period.
Scope
The study includes patients from 8 primary health care
centers (PHCC) from the Community of Madrid: 2
urban ones (PHCC Avenida de Aragón, PHCC Benita de
Avila), 3 suburban ones (PHCC Alameda de Osuna,
PHCC El Puerto, PHCC Jaime Vera), and 3 rural ones
(PHCC Paracuellos de Jarama, PHCC Las Matas, PHCC
Fronteras), which attend a total population of approxi-
mately 205,000.
Patients
All patients who are over 65 years old, diagnosed with
HTN and/or hypercholesterolemia, and included in a
program for following-up chronic patients in PHCCs
will be included. The patient must be under treatment
with at least one of the following drugs: enalapril, amlo-
dipine, and simvastatin, with a stable dose during the
previous 3 months, and must give informed, written
consent.
The criteria for exclusion are: having difficulty to
properly understand written or spoken Spanish, foresee-
ing an address change and not being ascribed to the
PHCC for the following year, and suffering from severe
systemic disease or other limitations that prevent the pa-
tient from attending the PHCC for the follow-up visits.
Sample size
Sample size has been calculated to estimate a propor-
tions difference in the degree of adherence to the treat-
ment of 20% between the exposed group (drug changes
at the pharmacy) and the non-exposed group. It is esti-
mated that adherence to treatments in the population
undergoing chronic treatment is 50%, and the odds ratio
(OR) of suffering an event of adherence decrease is
double in the group exposed to drug changes (OR = 2)
versus the non-exposed one.
For an alpha error of 0.05 and a beta error of 0.20, 237
patients would be necessary. Taking into account the ef-
fect of the doctor on adherence of their patients to treat-
ment, it is considered that the outcome of each patient
is not independent from other patients from the same
cluster, so it is necessary to adjust the sample size be-
cause of the design effect. Considering that the number
of included patients per doctor is 15, and assuming an
intraclass correlation coefficient of 0.01 [17], the
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loss of patients to follow-up within a one-year period,
the final sample size will be 259 patients.
Sampling
Random sampling will be performed out of the list of
patients who fit the selection criteria (≥65 years old,
HTN and/or dyslipidemia, and treated with any of the
3 studied drugs) from each of the 30 participating doc-
tors. Randomization will be performed by an independ-
ent researcher using computer software to create the
randomization sequence (Excel 2007).
Variables
The main outcome variable is a final combined variable,
defined as “having made some drug usage error and/or
an inadequate adherence to treatment regimen”.
Error in drug usage is defined according to the classifi-
cation proposed by Ruiz-Jarabo et al. [18]. The type of
error will be recorded (wrong dose, wrong frequency), as
well as if there was injury to the patient, in which case
the type and severity will also be recorded.
Inadequate adherence will be considered if more than
one forgotten dose is detected during the package count-
ing and/or if any of the answers (Yes/No) to the 4 ques-
tions of the Morisky-Green test in its validated Spanish
version [19] is wrong. In the case of discrepancies be-
tween the Morisky test and the counting, the outcome
of the counting will prevail. Since one single forgotten
dose is a very stringent level of accomplishment, if no
adherence differences are observed, different degrees of
adherence (80%, 90% and 110%) will be considered.
Secondary outcome variables
Sociodemographic
Age, sex, level of education (illiterate, without studies,
primary studies, secondary studies, superior education),
and PHCC.
Related to the prescription and active ingredient:
 Prescribed active ingredient: enalapril, amlodipine,
or simvastatin.
 Change of drug presentation at the pharmacy
(Yes/No).
 Number of changes per drug.
 Suffering an adverse reaction to the drug
(Yes/No), interruption of medication
(Yes/No), and the reason for
such interruption.
 Number of avoidable and non-avoidable
adverse
effects during the follow-up period.
 Tolerance of the patients to the dispensed drugs
according to their own direct statement.Clinical and analytical:
 Years of development of HTN and/or dyslipidemia.
Presence of pathologies that modify the HTN
(nephropathologies, sleep apnea, obesity, and
malnutrition). Presence of pathologies that modify
the lipid profile (hyperthyroidism, hypothyroidism,
obesity, and malnutrition). Comorbidity
(cardiovascular pathology, neurological pathology).
 Treatments that modify BP and the lipid profile
(diuretics, alpha and beta blockers), anti-
inflammatories, antidepressants and anxiolytics,
thyroxin, hormone replacement therapy. Other
concomitant treatments.
 Figures of systolic blood pressure (SBP) and diastolic
blood pressure (DBP) in each visit. Difference of SBP
and DBP between the first visit and the last
recorded data. Percentage of patients with good
control at the beginning and at the end of the study.
 Total HDL cholesterol, LDL cholesterol, and
triglycerides, both initial and after one year.
 Initial and final weight. Initial height. Difference in
body mass index (BMI) between the first and final
visits.
Data collection
Recruitment of patients will be done by their doctor
(a study researcher) during a primary care consultation,
who will collect the data for the various variables by
means of a personal interview and review of the comput-
erized clinical record, after having obtained informed
consent, and will record it in an electronic notebook for
data collection (Figure 1).
The study entails 5 visits during the trial period, set at
0, 3, 6, 9, and 12 months. Table 1 describes the visits
scheme and the variables and measurements to be re-
corded during each one.
If adverse effects are detected, the notification system
for adverse reactions will be followed according to
standard clinical practice.
In the case that one patient does not attend a visit, at
least 3 attempts to contact them by phone will be per-
formed during different days and hours. Patients lost to
follow-up and abandonments will be recorded and the
reasons noted.
Data analysis
Data will be reviewed prior to analysis to guarantee its
quality. A descriptive analysis will be performed on the
characteristics (age and sex) of patients who refuse to
participate in the study and the reasons for it will be
described.
A descriptive analysis of each of the variables will be
carried out. The mean and typical deviation will be
Figure 1 General scheme of the study. Randomization and
patient follow-up.
Arancon-Monge et al. BMC Public Health  (2015) 15:211 Page 5 of 7calculated in the case of symmetric distributions, and
median and interquartile ranges will be estimated if the
distribution is asymmetric. For categorical data, the fre-
quency and percentage distributions will be shown. The
difference of proportions will be estimated with its rele-
vant confidence interval of 95%.Table 1 Visits and procedures to be performed
Visit 1 Screening
(0 months)
Recruitment following the selection criteria X
Informed consent X




Lipid profile control X
Counting of drug packages
Morisky-Green test X
Data collection for errors and adverse effects
Collection of followed-up clinical variablesThe association of each of the independent variables
with the dependent variable (adherence decrease and
medication errors) will be studied, using Pearson’s Chi-
square test or Fisher’s exact test (when the conditions to
apply Chi-square are not satisfied) as the statistical tools
to compare proportions, and the Student’s T distribution
or the Mann–Whitney U non-parametric test to com-
pare the means.
A multivariate test with a logistic regression model will
be performed, using the final combined variable (adher-
ence and medication errors) as the dependent variable,
and using as independent variables those identified to be
associated in the bivariate analysis. All the hypothesis
testing will be performed for all analysis’, and a p < 0.05
will be accepted as significant. All the analysis methods
will be adjusted considering cluster randomizations [20].
Statistical data analysis will be performed using SPSS
18.0 software.
Ethical considerations
This study has been approved by the Clinical Research
Ethics Board of the Hospital de La Paz (February 5,
2012) in Madrid, and by the Central Research Board of
Primary Health Care of the Community of Madrid.
The study will be carried out in accordance with Span-
ish law, complying with regulation on protection of per-
sonal data and patient’s autonomy law. Patients will
receive information about the study, both written and
oral, and written consent will be obtained from all the
participants prior to their inclusion in it.
Discussion
In our environment, the effects that new legislative mea-
sures related to drug prescription may have on the safety
of the patient are unknown. For chronic treatment, the
interchangeability of drugs with different package ap-
pearances and presentations for the same active ingredi-
ent may lead to mistakes when choosing the package, or
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X
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X X X X
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cation. These errors may be much more frequent in
more vulnerable populations, such as elderly or multi-
medicated patients.
Patients will be included and monitored in the study
by their own primary care doctors according to standard
practice. Including patients from different health profes-
sionals implies an increase of variability on the one
hand, but on the other hand guarantees a lower number
of losses to follow-up since they are chronic patients
over 65 years old who periodically attend the PHCC,
therefore enabling the analysis of the outcome under
conditions of real clinical practice.
It must be highlighted that, in Spain, the majority of
the population with the most prevalent chronic patholo-
gies, such as HTN and dyslipidemia, is attended and su-
pervised in primary health care.
In order to decrease the variability among health pro-
fessionals, training sessions will be held and the protocol
for the follow-up of hypertensive patients in primary
health care in Madrid will be respected, having been im-
plemented in the data collection notebook. Homolo-
gated, calibrated blood pressure meters will be used in
order to guarantee the reliability of BP measurements.
We consider that despite the limitations that an obser-
vational study may have for answering our question,
namely the lack of feasibility of performing a clinical
trial as a result of not being able to randomize the inter-
vention (interchangeability of drugs at the pharmacy), it
will provide information on the possible effects that the
recent legislative changes may have on patient safety.
The management of pharmaceutical services must be
focused on both clinical and economic aspects, and
must encompass all levels: prescription, dispensing, pa-
tients drug intake, and even the manufacturing by fol-
lowing the principle “if they are the same, make them
look the same”. The legislation changes based only on
cost reduction and forgetful about improvement in med-
ical prescription and pharmaceutical service may worsen
the clinical situation and increase the consumption of
resources in the long term. The most important is that
the patient be the real aim for the outcome of all mea-
sures taken to improve their care.
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